Citrix Systems, Inc. (NasdaqGS: CTXS) reported a 12 percent jump in second-quarter earnings Wednesday, helped by a 17 percent rise in sales.
The company’s profit missed Wall Street expectations, but a stronger-than-expected forecast for this quarter and the full year helped boost Citrix shares in extended trading.
The company, which provides software and equipment for streamlining business computer systems, earned $47.6 million, or 25 cents per share, in the quarter ended June 30. That’s up from $42.5 million, or 23 cents per share, a year ago.
Shares of CTXS jumped $7.62 (+16.10%), up to $54.95 in early trading, today!
More about CTXS at: www.citrix.com
*****
Zamage Digital Art Imaging, Inc.’s (PINK SHEETS:ZMGD); subsidiary EverdowCRM Inc. (http://www.everdow.com/Everdow_EN/) has announced that the company has developed some 100 applications (Apps) for the iPhone and iPad that will soon be available in Apple Inc.’s App Store.
Everdow has been developing Apps software for the last three months, and total daily sales have reached approximately $500 USD. With the new Apps now approved for sale in Apple’s widely popular online App Store, sales of Everdow-developed Apps should increase dramatically. Because mobile offices are becoming the norm in many fast-paced industries, corporations increasingly view smart phones such as the iPhone as an essential business tool. More than 70% of Fortune 100 companies are testing the iPhone as their smart phone of choice.
More about ZMGD at: www.zamagedigitalcorp.com
*****
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson’s disease psychosis (PDP).
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
Shares of ACAD increased $0.30 (+27.78%), up to $1.38 in midday market trading, today!
More about ACAD at: www.acadia-pharm.com
Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup
******************************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.read more Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty-five thousand dollars from a third party for (30) days of advertisement services for Zamage Digital Art Imaging, Inc. (OTC: ZMGD.PK).
